U.S. markets closed

Oxford Biomedica plc (OXB.L)

LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
Add to watchlist
450.00-16.00 (-3.43%)
At close: 04:35PM BST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close466.00
Bid452.00 x 0
Ask453.50 x 0
Day's Range448.50 - 485.50
52 Week Range414.00 - 1,678.00
Avg. Volume228,738
Market Cap432.337M
Beta (5Y Monthly)0.93
PE Ratio (TTM)1,956.52
EPS (TTM)0.23
Earnings DateSep 20, 2022 - Sep 26, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1,349.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for OXB.L

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Benzinga

      Oxford Biomedica Inks New Three Year Deal To Make AstraZeneca's COVID-19 Vaccine

      Oxford Biomedica plc (OTC: OXBDF) signed a new three-year agreement to potentially make AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine beyond 2022. The new agreement represents an expansion of the original master supply and development agreement announced between the two companies in September 2020. The manufacture of COVID-19 vaccines at Oxford Biomedica's Oxbox facility, as part of the original commitment, is expected to complete in the last quarter of 2022. Under the expanded deal, AstraZen

    • Financial Times

      Oxford BioMedica extends Covid vaccine deal with AstraZeneca

      Oxford BioMedica has extended its partnership with AstraZeneca, agreeing a new three-year contract to manufacture Covid-19 vaccines if the UK drugmaker presses on with mass production of the jab. The specialist pharmaceutical manufacturer, which also makes cell and gene therapies, will make its Oxbox facility available on an “as needed” basis to AstraZeneca after 2022. The original contract signed in September 2020 is expected to complete in the last quarter of this year, with Oxford BioMedica recognising roughly £30mn from AstraZeneca this financial year.

    • Simply Wall St.

      Could The Market Be Wrong About Oxford Biomedica plc (LON:OXB) Given Its Attractive Financial Prospects?

      Oxford Biomedica (LON:OXB) has had a rough three months with its share price down 35%. However, stock prices are...